Monoamine oxidases (MAOs) and the histone demthylase LSD1 are evolutionarily related enzymes that catalyze the oxidative deamination of their substrates. They represent a spectacular example of how similarities in the chemistry of the catalyzed reaction can constrain evolution, despite different biological functions and cellular localizations. MAOs bind the outer mitochondrial membrane and play a central role in the metabolism of neurotransmitters such as dopamine and serotonin. MAO's rise to prominence in the biomedical community originated in the early fifties from Zeller's finding that MAO was the target for hydrazine inhibition which could function in treating depression. Since then, a huge number of MAO inhibitors have been developed and several of them have been used for the treatment of Parkinson's disease and depression. Our structural studies have shown that most of the known MAO inhibitors function through a mechanism-based mode that generates a covalent adduct with the FAD cofactor. LSD1 is a more recently discovered enzyme. It is responsible for the demethylation of Lys4 of histone H3. LSD1 is implicated in tumorigenesis and there are increasing efforts to identify LSD1 inhibitors. The crystal structure of LSD1 reveals a different substrate-binding site but similar catalytic machinery compared to those exhibited by MAO structures. This similarity is proving to be particularly insightful, prompting researchers to exploit the knowledge gained from MAO inhibition studies to develop effective LSD1 inhibitors. We shall present a comparative analysis of LSD1 and MAOs with a focus on the relevance of the structural investigations for understanding the mechanisms drug action and for the design of new inhibitor molecules targeting these amine oxidase enzymes.
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A family wide approach to structure-based inhibitor design for protein tyrosine phosphatases The protein tyrosine phosphatase (PTP) family is a large and diverse group of enzymes that together with protein tyrosine kinases control signaling pathways in the cell. Deregulation of PTPs has been linked to a range of human diseases, including cancer, diabetes, obesity and arthritis, and certain members of the family are recognised drug targets. PTPs exhibit high similarity in their overall fold but changes in the region surrounding the active site pocket can be exploited to achieve inhibitors through structure based rational design. We have screened a focused compound library and identified several small molecule inhibitors of PTPs many of which are selective against certain members of the family. In a biochemical assay these compounds inhibit phosphatase activity with IC50 values in the low micro molar range. At the Structural Genomics Consortium (SGC) PTPs have been studied for several years and 22 structures have been deposited in the protein data bank. With successful protocols for producing well diffracting crystals in place we are now developing a family based method for soaking crystals with the established inhibitors. The aim is to produce chemical probes specific for particular PTPs but to find means of taking advantage of the similarities between members of the family to reach this goal. Results with PTPs have so far identified crystal forms where the active site is in the open conformation due to crystal contacts between neighbouring molecules. This conformation is not optimal for binding compounds that inhibit activity, thus new crystal forms are being sought. By August, the latest results will be presented together with the evolved methodology for high-throughput generation of complex structures. Monochromatic time-resolved diffraction experiments of excitedstate geometry are flux limited even at third generation sources. For sub-microsecond experiments polychromatic techniques are needed. To avoid the known complexities of the Laue method we use a 'raw intensity' technique in which the intensity response to laser irradiation is directly extracted from dark-light pairs of frames, C38
